Amylyx Pharmaceuticals Seeks $350M in Public Stock Offering — Amylyx Pharmaceuticals, Inc.

Event summary

Amylyx Pharmaceuticals has launched a $350M public offering of common stock, with an additional $52.5M option for underwriters.
Proceeds will fund pre-commercial activities for avexitide, R&D, and working capital.
The offering is underwritten by Leerink Partners, Morgan Stanley, Guggenheim Securities, and LifeSci Capital.
The shares are being offered under a shelf registration statement filed with the SEC in March 2026.

The big picture

Amylyx's $350M offering reflects the biotech sector's reliance on public markets to fund late-stage drug development. The move comes as Amylyx seeks to scale its pre-commercial activities for avexitide, a critical phase for biotech firms aiming to transition from clinical trials to market-ready therapies. The involvement of top-tier underwriters underscores investor interest in the neurodegenerative disease space, though execution risks remain high.

What we're watching

Execution Risk: How Amylyx will deploy the $350M to accelerate avexitide's commercialization and R&D pipeline.
Market Dynamics: Whether the offering will strengthen Amylyx's position in the competitive neurodegenerative disease space.
Financial Health: The pace at which Amylyx can sustain its cash burn rate post-offering.